150 related articles for article (PubMed ID: 24570340)
21. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
[TBL] [Abstract][Full Text] [Related]
22. Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects.
Panhard X; Samson A
Biostatistics; 2009 Jan; 10(1):121-35. PubMed ID: 18583352
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
24. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
25. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
26. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
29. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
30. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Chan PL; Jacqmin P; Lavielle M; McFadyen L; Weatherley B
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):41-61. PubMed ID: 21088872
[TBL] [Abstract][Full Text] [Related]
31. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
[TBL] [Abstract][Full Text] [Related]
34. Extending the code in the open-source saemix package to fit joint models of longitudinal and time-to-event data.
Lavalley-Morelle A; Mentré F; Comets E; Mullaert J
Comput Methods Programs Biomed; 2024 Apr; 247():108095. PubMed ID: 38422892
[TBL] [Abstract][Full Text] [Related]
35. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
[TBL] [Abstract][Full Text] [Related]
36. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
37. Pediatric Gaucher experience in South Marmara region of Turkey.
Erdemır G; Özkan T; Özgür T; Yazici Z; Özdemır Ö
Turk J Gastroenterol; 2011 Oct; 22(5):500-4. PubMed ID: 22234757
[TBL] [Abstract][Full Text] [Related]
38. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
Starzyk K; Richards S; Yee J; Smith SE; Kingma W
Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
[TBL] [Abstract][Full Text] [Related]
39. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
